KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Cash & Equivalents: 2009-2024

Historic Cash & Equivalents for Ionis Pharmaceuticals (IONS) over the last 16 years, with Dec 2024 value amounting to $242.1 million.

  • Ionis Pharmaceuticals' Cash & Equivalents rose 1.12% to $338.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $338.3 million, marking a year-over-year increase of 1.12%. This contributed to the annual value of $242.1 million for FY2024, which is 39.37% down from last year.
  • Per Ionis Pharmaceuticals' latest filing, its Cash & Equivalents stood at $242.1 million for FY2024, which was down 39.37% from $399.3 million recorded in FY2023.
  • Ionis Pharmaceuticals' 5-year Cash & Equivalents high stood at $869.2 million for FY2021, and its period low was $242.1 million during FY2024.
  • Its 3-year average for Cash & Equivalents is $305.9 million, with a median of $276.5 million in 2022.
  • Per our database at Business Quant, Ionis Pharmaceuticals' Cash & Equivalents spiked by 118.57% in 2021 and then plummeted by 68.19% in 2022.
  • Ionis Pharmaceuticals' Cash & Equivalents (Yearly) stood at $397.7 million in 2020, then soared by 118.57% to $869.2 million in 2021, then slumped by 68.19% to $276.5 million in 2022, then skyrocketed by 44.41% to $399.3 million in 2023, then crashed by 39.37% to $242.1 million in 2024.